(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of -5.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Ptc Therapeutics's revenue in 2024 is $937,822,000.On average, 6 Wall Street analysts forecast PTCT's revenue for 2024 to be $46,467,902,933, with the lowest PTCT revenue forecast at $35,982,791,691, and the highest PTCT revenue forecast at $51,771,400,242. On average, 6 Wall Street analysts forecast PTCT's revenue for 2025 to be $47,191,159,344, with the lowest PTCT revenue forecast at $25,495,152,384, and the highest PTCT revenue forecast at $57,300,431,591.
In 2026, PTCT is forecast to generate $63,978,966,430 in revenue, with the lowest revenue forecast at $41,605,821,093 and the highest revenue forecast at $89,700,342,327.